Notably, dual therapy combining GITR ligand (GITRL) with nivolumab (an anti-PD1 antibody) was shown to enhance the expansion of CD8+ TILs and improve the reinvigoration of IFN-γ secretion by exhausted CD8+ TILs from primary CRC (206). Here, TNFRSF18 is linked to colorectal carcinoma.